SYRE · Spyre Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $124.98
Note written ·
Price against the kill line
16.8% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $124.98, on record since 11 November 2026. The shares are down 0.6% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $124.98, over the 52-week intraday high of $110.64 set on 9 November 2026, which would show the shares leading the S&P 500. Combination data in ulcerative colitis showing clear efficacy gains over single agents would also show the shares leading.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 3 November 2026
- Net cash, cash less debt ($M)
- 1,100
All filed numbers
What Spyre Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | −96.1 |
| Net income ($M) four quarters: −264 | −96.1 |
| Diluted shares, change on a year (%) | Not reported |
| Operating cash flow ($M) | −249 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 1,100 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 1,100 |
| Deferred revenue ($M) at 31 December 2025, filed 19 February 2026 | 0.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 1,052 |
| Market value ($M) | 9,877 |
| Enterprise value, market value plus net debt ($M) no debt reported | 8,777 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 9.4 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 13.2% of shares outstanding sold short, 7.3 days of average trading to cover, −2.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $12.3M |
| 12 monthsfrom | $0 | $441.9M |
The thesis
Spyre Therapeutics' shares are more likely to lag the S&P 500 over the next three months. All three of its inflammatory bowel disease (IBD) antibodies cleared single-agent proof of concept, but the next human evidence, the ulcerative colitis combination data guided to the third quarter of 2027, is about ten months away, and the company keeps selling stock.
The antibody for the TL1A target, SPY072, missed its primary endpoints in psoriatic arthritis and axial spondyloarthritis, the company reported on 3 November 2026. It does not plan to advance the drug in rheumatic diseases. The shares closed at $96.59 on 5 November 2026 and $109.00 on 9 November 2026, so the market looked through the miss. Spyre had said on 25 August 2026 that the rheumatoid arthritis effect was too small to prioritise.
The shares closed at $102.91 on 12 November 2026. That is above the $85.00 price of the October 2026 offering and above both the 50-day average of $91.15 and the 200-day average of $76.32. The market has already priced in the single-agent IBD results and a clean financing; the combination readout is what could add to that.
Bullish and bearish views on Spyre Therapeutics, Inc.
The bull case on Spyre Therapeutics, Inc. (SYRE), in brief: each IBD component cleared proof of concept. The bear case: SPY072 failed in two more rheumatic diseases.
Bull case
- Each IBD component cleared proof of concept. On 8 September 2026, SPY003 (anti-IL-23) met its primary endpoint in Part A of the Phase 2 SKYLINE ulcerative colitis trial, with 20% clinical remission and 30% endoscopic improvement at week 12. The company said SPY001 and SPY002 had met their Part A endpoints in April and June 2026.
- Combination data is on track. Spyre said on 3 November 2026 that SKYLINE Part B is enrolling ahead of schedule and expects induction topline data for the SPY120, SPY130 and SPY230 combinations in the third quarter of 2027.
- Cash funds the plan into 2029. Cash, equivalents and marketable securities were $1,071.9 million at 30 September 2026. Pro forma cash was $1,467.9 million including $378.0 million of net offering proceeds and $18.0 million of October at-the-market sales, and the company guides runway into the second half of 2029 (Q3 2026 results, 3 November 2026).
- A new use for the TL1A antibody. The Phase 2 SKYLIGHT trial of SPY072 with bimekizumab in hidradenitis suppurativa started in September 2026. Week 16 results are planned for late 2027 or early 2028.
- Analysts remain constructive. Guggenheim kept Buy and raised its target to $135 on 4 November 2026. Wedbush kept Outperform the same day but lowered its target to $120 (Benzinga analyst-action headlines).
Bear case
- SPY072 failed in two more rheumatic diseases. The 3 November 2026 results release reported misses in psoriatic arthritis (ACR20 response) and axial spondyloarthritis (ASDAS change). The company did not disclose response rates or effect sizes for either study.
- Losses are widening. Research and development expense for the third quarter of 2026 was $89.2 million against $45.2 million a year earlier. The net loss was $96.1 million and operating cash use was $77.5 million.
- Stock keeps coming to market. Spyre sold shares at $85.00 in October 2026 ($350.0 million gross) and at $62.00 in April 2026 ($403.0 million gross). It sold $18.0 million under the at-the-market program in October, and the 26 June 2026 agreement allows up to $500.0 million. Common shares outstanding rose to 89,953,997 at 30 September 2026 from 78,189,811 at 31 December 2025.
- The core claim is untested in people. The platform rests on the idea that combining antibodies beats single drugs. Mouse colitis data presented on 19 October 2026 favoured combinations, but human data does not arrive until the third quarter of 2027.
- Executives sold into the rally. SEC Form 4 filings show Chief Executive Officer Cameron Turtle sold 15,000 shares at an average of $92.01 on 1 October 2026. Chief Financial Officer Scott Burrows sold 25,000 shares at an average of $90.47 on 30 September to 1 October 2026. Heidy King-Jones sold 28,933 shares at an average of $91.03 on 1 October 2026. All three sales ran under Rule 10b5-1 plans, which are pre-arranged selling schedules.
Price setup
The shares closed at $102.91 on 12 November 2026, 7.0% below the 52-week intraday high of $110.64 set on 9 November 2026. The 52-week closing low is $22.63 on 13 November 2025. The three-month change is –0.7%, measured from the $103.63 close on 14 August 2026.
The recent path ran from $96.59 on 5 November 2026 to $103.86 on 6 November 2026 and $109.00 on 9 November 2026. Closes of $104.48 on 10 November 2026, $106.82 on 11 November 2026 and $102.91 on 12 November 2026 followed. The shares sit 12.9% above the 50-day average of $91.15 and 34.8% above the 200-day average of $76.32, both as of 12 November 2026.
The $85.00 October offering price is the level at which the most recent large buyers came in. Spyre has also scheduled fireside chats with UBS and Jefferies in London and with Evercore and Citi in Miami, per its 10 November 2026 release.
Catalysts ahead
- 16 November 2026: Spyre fireside chat at the UBS conference in London (1:20 pm GMT). Management commentary on the SKYLINE Part B timeline and financing is the near-term information source, since no trial data is due.
- 17 November 2026: Spyre fireside chat at the Jefferies conference in London (3:00 pm GMT). A second chance to hear management on combination-trial enrollment and the SPY072 hidradenitis suppurativa plan.
- 1 December 2026: Spyre fireside chat at the Evercore conference in Miami (3:00 pm ET). Further management comment ahead of year end; no company data release is scheduled.
- 2 December 2026: Spyre fireside chat at the Citi conference in Miami (9:40 am ET). Last scheduled appearance of 2026; any change to the Q3 2027 combination-data guidance would show up here or in a filing.
- ~30 September 2027 (est., Q3 2027): SKYLINE Part B induction topline data for SPY120, SPY130 and SPY230 combinations in ulcerative colitis. First human evidence on whether combining the antibodies beats single drugs, the platform's core claim.
- ~31 December 2027 (est.): SKYLIGHT Week 16 results for SPY072 with bimekizumab in hidradenitis suppurativa (guided late 2027 or early 2028). Decides whether the TL1A antibody has a path to pivotal studies after the rheumatic disease misses.
What would change the view
A daily close above $124.98, over the 52-week intraday high of $110.64 set on 9 November 2026, which would show the shares leading the S&P 500. Combination data in ulcerative colitis showing clear efficacy gains over single agents would also show the shares leading.
What it trades with
Spyre trades with clinical-stage immunology and gastroenterology biotech, and with the biotech funding climate, since it raised equity twice in 2026. Read-throughs come from the TL1A class (Merck's tulisokibart and Roche's afimkibart) and from IL-23 and integrin competitors in ulcerative colitis. Spyre has no approved product and no revenue, so its shares respond to trial news, financing and analyst targets more than to quarterly financial results.
The evidence, claim by claim (8)
- Cash, equivalents and marketable securities were $1,071.9 million at 30 September 2026; pro forma cash was $1,467.9 million including $378.0 million net offering proceeds and $18.0 million of October at-the-market sales; runway guided into the second half of 2029. Spyre Q3 2026 results release, 3 November 2026 · as of
- SPY072 missed primary endpoints in psoriatic arthritis and axial spondyloarthritis; the company does not plan to advance it in rheumatic diseases. Spyre Q3 2026 results release, 3 November 2026 · as of
- SKYLINE Part B is enrolling ahead of schedule; induction topline data for SPY120, SPY130 and SPY230 combinations are expected in the third quarter of 2027. Spyre Q3 2026 results release, 3 November 2026 · as of
- Third-quarter 2026 research and development expense was $89.2 million versus $45.2 million a year earlier; net loss was $96.1 million; operating cash use was $77.5 million. Spyre Q3 2026 results release and Form 10-Q · as of
- Common shares outstanding were 89,953,997 at 30 September 2026, versus 78,189,811 at 31 December 2025. Spyre Q3 2026 results release · as of
- Guggenheim maintained Buy and raised its target to $135; Wedbush maintained Outperform and lowered its target to $120. Benzinga analyst-action headlines · as of
- Chief Executive Officer Cameron Turtle sold 15,000 shares at an average of $92.01 on 1 October 2026 under a Rule 10b5-1 plan; Chief Financial Officer Scott Burrows sold 25,000 shares at an average of $90.47 over 30 September to 1 October 2026. SEC Form 4 filings, 2 October 2026 · as of
- Spyre will present at UBS (16 November 2026) and Jefferies (17 November 2026) conferences in London and Evercore (1 December 2026) and Citi (2 December 2026) conferences in Miami. Spyre press release, 10 November 2026 · as of
Sources
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…
ABVX
Abivax SA
Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative…
BHVN
Biohaven
Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over three months: the SK Biopharmaceuticals licence has cleared US…